Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in NASH

The study aims to further validate the anti-fibrotic and anti-inflammatory activity of CM-101 while providing safety and PK data to support development of the subcutaneous formulation

TEL-AVIV, Israel, April 26, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, today announced enrollment of the first patient in its Phase 2a study of CM-101 in Non-Alcoholic Steatohepatitis (NASH). CM-101 is a first-in-class humanized monoclonal antibody designed to bind to and block CCL24 activity, an important chemokine activity that stimulates inflammation and the development of fibrosis.

Read More